<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229528</url>
  </required_header>
  <id_info>
    <org_study_id>1000774</org_study_id>
    <nct_id>NCT00229528</nct_id>
  </id_info>
  <brief_title>Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease</brief_title>
  <official_title>Dose Ranging Study of the Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <brief_summary>
    <textblock>
      COAT-platelets stands for collagen and thrombin stimulated platelets, which are two things in&#xD;
      the body that make platelets stick together. These platelets may be important in the&#xD;
      initiation of a heart attack (myocardial infarction). A chemical in the body called serotonin&#xD;
      maybe responsible for COAT-platelet production. Paroxetine causes a significant reduction in&#xD;
      platelet serotonin and therefore may have value in preventing heart attacks. Therefore, the&#xD;
      current study is designed to determine whether paroxetine will decrease COAT-platelet&#xD;
      production in normal volunteers and patients with cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define the percent COAT-platelet and response to Paxil-CR in 5 control subjects.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To define the percent COAT-platelet and response to Paxil-CR in 20 patients with Coronary Artery Disease.</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paxil-CR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  normal volunteers (without heart disease)&#xD;
&#xD;
          -  patients with heart disease&#xD;
&#xD;
          -  between ages 18 &amp; 65&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  children less than 18 years&#xD;
&#xD;
          -  adults greater than 65 years&#xD;
&#xD;
          -  those who can not keep appointments&#xD;
&#xD;
          -  patients within 2 weeks of a coronary catheterization&#xD;
&#xD;
          -  patients within 6 months of unstable angina or myocardial infarction&#xD;
&#xD;
          -  individuals with allergies to paroxetine or similar medications&#xD;
&#xD;
          -  individuals having adverse events to paroxetine or similar medications&#xD;
&#xD;
          -  individuals with diagnosis of mania&#xD;
&#xD;
          -  individuals with a diagnosis of hypomania&#xD;
&#xD;
          -  individuals with a diagnosis of bipolar disorders&#xD;
&#xD;
          -  individuals with a diagnosis of depression&#xD;
&#xD;
          -  individuals with a diagnosis of panic disorders&#xD;
&#xD;
          -  individuals with a diagnosis of seizure disorders&#xD;
&#xD;
          -  individuals with a history of suicide attempts&#xD;
&#xD;
          -  individuals with a diagnosis of hyponatremia&#xD;
&#xD;
          -  individuals with active bleeding disorders&#xD;
&#xD;
          -  individuals with a diagnosis of narrow angle glaucoma&#xD;
&#xD;
          -  individuals with an estimated creatinine clearance of less that 30 ml/min&#xD;
&#xD;
          -  individuals taking potentially interacting medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen F. Hamilton, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Oklahoma College of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>September 19, 2008</last_update_submitted>
  <last_update_submitted_qc>September 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Stephen Hamilton</name_title>
    <organization>University of Oklahoma Dept of Pharmacy</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

